These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 23946196)

  • 21.
    Sutton TC; Lamirande EW; Bock KW; Moore IN; Koudstaal W; Rehman M; Weverling GJ; Goudsmit J; Subbarao K
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29046448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.
    Wei CJ; Boyington JC; McTamney PM; Kong WP; Pearce MB; Xu L; Andersen H; Rao S; Tumpey TM; Yang ZY; Nabel GJ
    Science; 2010 Aug; 329(5995):1060-4. PubMed ID: 20647428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutralizing Antibody Responses to Homologous and Heterologous H1 and H3 Influenza A Strains After Vaccination With Inactivated Trivalent Influenza Vaccine Vary With Age and Prior-year Vaccination.
    Wang W; Chen Q; Ford-Siltz LA; Katzelnick LC; Parra GI; Song HS; Vassell R; Weiss CD
    Clin Infect Dis; 2019 May; 68(12):2067-2078. PubMed ID: 30256912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Seasonal H1N1 2007 influenza virus infection is associated with elevated pre-exposure antibody titers to the 2009 pandemic influenza A (H1N1) virus.
    Lemaitre M; Leruez-Ville M; De Lamballerie XN; Salez N; Garrone P; Fluckiger AC; Klatzmann D; Carrat F
    Clin Microbiol Infect; 2011 May; 17(5):732-7. PubMed ID: 20731679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ferret model to mimic the sequential exposure of humans to historical H3N2 influenza viruses.
    Chiba S; Hatta M; Pattinson D; Yasuhara A; Neumann G; Kawaoka Y
    Vaccine; 2023 Jan; 41(2):590-597. PubMed ID: 36517323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
    Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses.
    Krause JC; Tsibane T; Tumpey TM; Huffman CJ; Albrecht R; Blum DL; Ramos I; Fernandez-Sesma A; Edwards KM; García-Sastre A; Basler CF; Crowe JE
    J Virol; 2012 Jun; 86(11):6334-40. PubMed ID: 22457520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virus-neutralizing antibody response of mice to consecutive infection with human and avian influenza A viruses.
    Janulíková J; Stropkovská A; Bobišová Z; Košík I; Mucha V; Kostolanský F; Varečková E
    Acta Virol; 2015 Jun; 59(2):166-73. PubMed ID: 26104333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Monoclonal antibodies with high virus-neutralizing activity against pandemic influenza virus A/llV-Moscow/01/2009 (H1N1)swl].
    Klimova RR; Masalova OV; Burtseva EI; Chichev EV; Lesnova EI; Oskerko TA; Mukasheva EA; Rudneva IA; Lvov DK; Kushch AA
    Vopr Virusol; 2011; 56(3):15-20. PubMed ID: 21786621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutralizing and protective epitopes of the 2009 pandemic influenza H1N1 hemagglutinin.
    Schmeisser F; Friedman R; Besho J; Lugovtsev V; Soto J; Wang W; Weiss C; Williams O; Xie H; Ye Z; Weir JP
    Influenza Other Respir Viruses; 2013 May; 7(3):480-90. PubMed ID: 23122228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-neuraminidase antibodies against pandemic A/H1N1 influenza viruses in healthy and influenza-infected individuals.
    Desheva Y; Sychev I; Smolonogina T; Rekstin A; Ilyushina N; Lugovtsev V; Samsonova A; Go A; Lerner A
    PLoS One; 2018; 13(5):e0196771. PubMed ID: 29742168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades.
    Bragstad K; Martel CJ; Thomsen JS; Jensen KL; Nielsen LP; Aasted B; Fomsgaard A
    Influenza Other Respir Viruses; 2011 Jan; 5(1):13-23. PubMed ID: 21138536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re-emergence of H3N2 strains carrying potential neutralizing mutations at the N-linked glycosylation site at the hemagglutinin head, post the 2009 H1N1 pandemic.
    Ushirogawa H; Naito T; Tokunaga H; Tanaka T; Nakano T; Terada K; Ohuchi M; Saito M
    BMC Infect Dis; 2016 Aug; 16():380. PubMed ID: 27503338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for antigenic seniority in influenza A (H3N2) antibody responses in southern China.
    Lessler J; Riley S; Read JM; Wang S; Zhu H; Smith GJ; Guan Y; Jiang CQ; Cummings DA
    PLoS Pathog; 2012; 8(7):e1002802. PubMed ID: 22829765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preexisting antibody response against 2009 pandemic influenza H1N1 viruses in the Taiwanese population.
    Chi CY; Liu CC; Lin CC; Wang HC; Cheng YT; Chang CM; Wang JR
    Clin Vaccine Immunol; 2010 Dec; 17(12):1958-62. PubMed ID: 20876823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design.
    Wei CJ; Boyington JC; Dai K; Houser KV; Pearce MB; Kong WP; Yang ZY; Tumpey TM; Nabel GJ
    Sci Transl Med; 2010 Mar; 2(24):24ra21. PubMed ID: 20375007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Swine influenza virus antibodies in humans, western Europe, 2009.
    Gerloff NA; Kremer JR; Charpentier E; Sausy A; Olinger CM; Weicherding P; Schuh J; Van Reeth K; Muller CP
    Emerg Infect Dis; 2011 Mar; 17(3):403-11. PubMed ID: 21392430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralization and Binding Profile of Monoclonal Antibodies Generated Against Influenza A H1N1 Viruses.
    Shembekar N; Mallajosyula VV; Malik A; Saini A; Varadarajan R; Gupta SK
    Monoclon Antib Immunodiagn Immunother; 2016 Aug; 35(4):191-8. PubMed ID: 27463230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of amino acid substitutions supporting antigenic change of influenza A(H1N1)pdm09 viruses.
    Koel BF; Mögling R; Chutinimitkul S; Fraaij PL; Burke DF; van der Vliet S; de Wit E; Bestebroer TM; Rimmelzwaan GF; Osterhaus AD; Smith DJ; Fouchier RA; de Graaf M
    J Virol; 2015 Apr; 89(7):3763-75. PubMed ID: 25609810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
    Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
    Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.